Home » Posts tagged 'nhs'

Tag Archives: nhs

Malcolm Stacey of ShareProphets – Feedback PLC, Don’t You Hate the Small Profit-Takers?

7th October 2015 / Leave a comment

Hello Share Bunnies. There was some interesting share movements after all the good news came out for Feedback (FDBK), the minnow capitalised at a mere £5 million.

This firm which makes software to help in assessing cancers and other serious illnesses has been recording some big progress.

The latest news to come in was that the National Health Service’s research arm has produced ‘an alert’ to the affect that this company is worth looking at.

The share price put on 15%. It kept that level for most of the morning. Then the price began stepping up. There were small twitches until the golden share reached nearly a 50% rise on the day.

This put Feedback at the top of the overall winners board. But not for long. The zenith proved to be a spike and the share inched down again to end the day at just 15% up.

I checked the number of buys and sells throughout the day, and at no point did purchases exceed the sales.

This rise and fall pattern is so common for penny shares these days. And I think we all know what’s going on.There is a large army out there who will take a profit, no matter what the great future might lie in store for the company.

Feedback may not yet have recorded a recent profit, but it already nets £300,000 every 6 months by way of royalties and as their software is so desirable to find and treat serious cancers, I cannot see it failing to be a tasty go-er in the near future.

Yet, so many holding the share are willin to take a short term profit. And they do that even though the spread is, as I look now, 20%.

I think such short-term strategies are a mistake. They won’t realise much cash, because I notice the parcels of shares sold were largely tiny, many under £300.

This could be a multi-bagger. I’m not daft enough to say that’s certain, or even probable, but I’m buying the shares and staying in for a few months at least.

But what the heck? They say it’s never wrong to take a profit, and that does take a bit of arguing against. But personally I prefer a big profit to a small one.

Time now for sampling duty – at the Punter’s Return.

Malcolm Stacey has been writing about shares for more than 20 years. His first book “The Armchair Tycoon” was first published in 1998 but a revised 2014 e-version is now available. To obtain a FREE copy fill in the form HERE

– See more at: http://www.shareprophets.com/views/15556/don-t-you-hate-the-small-profit-takers-ref-feedback#sthash.oBmJQaPC.dpuf

Feedback PLC – NHS England “Alert” on potential application of TexRAD for assessing lung cancer patients

6th October 2015 / Leave a comment

Feedback plc is pleased to announce that the research arm of NHS England has published an “Alert” on the potential application of Feedback’s TexRAD CT texture analysis software for assessing patients with lung cancer. The National Institute for Health Research through its Horizon Scanning Research and Intelligence Centre (NIHR HSRIC) based at the University of Birmingham, England has also posted the Alert on its publicly accessible website. (www.hsric.nihr.ac.uk)

NIHR HSRIC is an academic unit which independently investigates and provides advanced notice of new and emerging medical devices and diagnostics that have the potential to positively impact upon the NHS within the next two years. Before writing the Alert, NIHR HSRIC looked at TexRAD CT texture analysis technology and its potential use for assessing patients with different cancers but particularly for those with lung cancer. The Alert will be distributed within the NHS and to national healthcare organisations and policy makers such as the National Institute for Health and Care Excellence (NICE) and the UK National Screening Committee.

Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company’s subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented: “The Alert from the NHS’s research arm is a significant step towards potentially obtaining NICE approval for TexRAD to be used as a clinical tool for assessing patients with lung cancer. This adds to the recently announced clinical adoption study focused on lung cancer being undertaken by Professor Ken Miles at the Princess Alexandra Hospital, Brisbane, Australia. “

For further information contact:

Feedback plc	Tel: 01954 718072
Simon Barrell / Trevor Brown / Tom Charlton

Sanlam Securities UK (Nominated Adviser and Joint Broker)	Tel: 020 7628 2200
Simon Clements / Virginia Bull

Peterhouse Corporate Finance Ltd(Joint Broker)	Tel: 020 7469 0936
Lucy Williams / Duncan Vasey

Notes to editors:

TexRAD is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than is readily visible to the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an ‘Imaging-Biomarker’) in confident decision-making: it has the potential to assess the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of ‘Precision and Personalized Medicine’. TexRAD is manufactured under licence by company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.

Health Service Journal – Only together can we beat cancer

6th August 2015 / Leave a comment

Collaboration between public and private organisations is vital if the NHS is to win the war on cancer, says Sanjeev Pandya, CEO of Advanced Oncotherapy (AVO).

The government’s latest strategy to improve cancer treatment in the UK is welcome, but extra funding alone is not the answer. Greater collaboration is the key to winning the war.

UK cancer survival rates have doubled over the past five decades. For the first time, those developing cancer stand more of a chance of surviving for 10 years or more than they do of getting the disease in the first place.

‘Cancer survival rates in the UK lag behind those achieved by many of our European cousins by more than two decades’
Despite this, cancer survival rates in the UK lag behind those achieved by many of our European cousins by more than two decades. The fight to close this gap, while continuing to improve patient outcomes, is one of the most profound facing our health service.

Future challenges

The problem is compounded by challenges on the road ahead. A growing population of older people, combined with improving patient outcomes for other conditions, mean there is greater demand for NHS oncology resources and palliative care.

Another issue is presented by the future of cancer treatment itself. Advances in medical technology and an increasingly sophisticated understanding of genetics is leading to a greater shift towards personalised medicine. Although highly effective, these treatments escalate per patient costs significantly.

All of these factors conspire to make the NHS’s war on cancer increasingly complex and challenging. They also serve to put a heightened strain on already limited budgetary resources.

Full article here

Health Service Procurement Is a Mess – the Military Has Answers – Huffington Post

12th May 2015 / Leave a comment

Health Service Procurement Is a Mess – the Military Has Answers – Huffington Post

Sanjeev Pandya
Chief Executive of Advanced Oncotherapy

Despite reform, the NHS’ procurement process still delivers poor value for money, stifles medical innovation and prevents new entrants to the market. It’s time to look to the military for solutions.

In 2002, the then Labour Health Secretary, Alan Milburn, announced plans for the establishment of Foundation Trusts. Seen as a radical shake up of the health service, by granting increased autonomy to local Trusts, Foundation status was seen as a mechanism to introduce much needed competition between hospitals. In turn, it was determined this competition would drive up clinical standards and curb wasteful spending, while also improving the managerial oversight of the health service as a whole. This internal ‘synthetic’ market was designed to incorporate the strengths of private healthcare provision, while retaining state control..

While Foundation Trusts have undoubtedly been successful in improving patient care and curbing wasteful spending in some areas, the system has also brought with it inherent disadvantages. One example of this is the procurement of high value medical equipment..

The news of the Health Department’s investment has already been superseded by developments in the private sector. In January it was announced that a pioneering private sector deal would see the delivery of a technically superior, more compact and lower cost proton therapy facility in the heart of London’s Harley Street. The next generation facility is set to come on stream a full year earlier than either of the two NHS centres..